Marksans Pharma Limited — Investor Meet, 20-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Marksans Pharma posted a stellar Q1 FY27: Revenue hit INR 841 Cr (+35.6% YoY), with highest-ever EBITDA of INR 213 Cr (+112.8% YoY) and PAT of INR 159 Cr (+173.9% YoY). Gross margin reached 59.1%, EBITDA margin 25.3%. Cash balance surpassed INR 1,000 Cr. Europe was a key driver, growing 74.7% YoY (including QliniQ acquisition), while North America grew 15.1%. Management expects sustainable gross margins of 55-56% and sticks to FY27 guidance of 15-20% revenue growth and 21-22% EBITDA margin. The company is confident about doubling revenue in five years, driven by strategic European expansion and inorganic growth.